Mepolizumab for treatment of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - A pilot study
Not Applicable
Recruiting
- Conditions
- DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndromeInflammatory and Immune System - Allergies
- Registration Number
- ACTRN12621001333808
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Adult patients (18 years old and above) who are diagnosed with DRESS syndrome (based on the RegiSCAR criteria) and with eosinophil count >0.8 x 10^9/L.
Exclusion Criteria
those with other eosinophilic disorders or concurrent parasitic infection, pregnant or breastfeeding patients, children and those who are unable to give informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie mepolizumab's efficacy in DRESS syndrome relapses?
How does mepolizumab compare to corticosteroids in managing DRESS syndrome symptoms?
Which biomarkers correlate with response to IL-5 inhibition in eosinophilic drug hypersensitivity?
What adverse events are associated with anti-IL5 therapy in systemic immune-mediated diseases?
Are there combination therapies involving mepolizumab for severe allergic and inflammatory conditions?